Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.71 |
| ▸ | CA12 | O43570 | 5/20 | 0.65 |
| ▸ | CA4 | P22748 | 5/20 | 0.65 |
| ▸ | CA9 | Q16790 | 5/20 | 0.65 |
| ▸ | CA6 | P23280 | 3/20 | 0.65 |
| ▸ | CA5A | P35218 | 3/20 | 0.65 |
| ▸ | CA7 | P43166 | 3/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.65 |
| ▸ | TTR | P02766 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13242547 | 0.94 | MET (0.70) | METCA12CA4CA9CA6 | |
| SCHEMBL13242551 | 0.92 | MET (0.64) | METCA12CA4CA9CA6 | |
| SCHEMBL13242549 | 0.90 | CA12 (0.72) | METCA12CA4CA9CA6 | |
| SCHEMBL1318303 | 0.90 | CA12 (0.72) | METCA12CA4CA9CA6 | |
| SCHEMBL13242550 | 0.89 | MET (0.64) | METCA12CA4CA9CA6 | |
| SCHEMBL1319077 | 0.87 | MET (0.67) | METCA12CA4CA9CA6 | |
| SCHEMBL13242532 | 0.87 | MET (0.67) | METCA12CA4CA9CA6 | |
| SCHEMBL2880951 | 0.87 | MET (0.67) | METCA12CA4CA9CA6 | |
| SCHEMBL13242533 | 0.87 | MET (0.69) | METCA12CA4CA9CA6 | |
| SCHEMBL1321817 | 0.87 | MET (0.69) | METCA12CA4CA9CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NOS1, NOS2, NOS3 | MET 4453/4885CA12 3464/4885CA4 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.